Methyl 4-(aminomethyl)thiophene-2-carboxylate | 195322-20-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: Methyl 4-(aminomethyl)thiophene-2-carboxylate
• CAS: 195322-20-4
• 化学式: C₇H₉NO₂S
• mdl: MFCD06803428
• 分子量: 171.22
• InChiKey: XQNRXJWIFJQYPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  二碳酸二叔丁酯 、 Methyl 4-(aminomethyl)thiophene-2-carboxylate 在 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 methyl 4-(((tert-butoxycarbonyl)amino)methyl)thiophene-2-carboxylate
  参考文献：
  名称：

  Aminomethylthiophene-2-carboxylic acids as dipeptide mimetic in new growth hormone secretagogues

  摘要：

  3-Aminomethylbenzoic acid is a well established dipeptide mimetic. Herein, aminomethylthiophene-2-carboxylic acids(1)) have been synthesized as analogues of 3-aminomethylbenzoic acid. Their use as a dipeptide-mimetic at the N-terminal of novel growth hormone secretagogues is described. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00348-x
• 作为产物：
  描述：

  4-(溴甲基)-2-噻吩羧酸甲酯 在 氨 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 Methyl 4-(aminomethyl)thiophene-2-carboxylate
  参考文献：
  名称：

  Aminomethylthiophene-2-carboxylic acids as dipeptide mimetic in new growth hormone secretagogues

  摘要：

  3-Aminomethylbenzoic acid is a well established dipeptide mimetic. Herein, aminomethylthiophene-2-carboxylic acids(1)) have been synthesized as analogues of 3-aminomethylbenzoic acid. Their use as a dipeptide-mimetic at the N-terminal of novel growth hormone secretagogues is described. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00348-x

文献信息

• Heterobicyclic metalloprotease inhibitors
  申请人：Steeneck Christoph

  公开号：US20070155738A1

  公开（公告）日：2007-07-05

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• Heterotricyclic metalloprotease inhibitors
  申请人：Gege Christian

  公开号：US20080207607A1

  公开（公告）日：2008-08-28

  The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
• Heterobicyclic Metalloprotease Inhibitors
  申请人：STEENECK Christoph

  公开号：US20090312312A1

  公开（公告）日：2009-12-17

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• Heterotricyclic Metalloprotease Inhibitors
  申请人：Gege Christian

  公开号：US20100087420A1

  公开（公告）日：2010-04-08

  The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
• HETEROBICYCLIC METALLOPROTEASE INHIBITORS
  申请人：Steeneck Christoph

  公开号：US20120015920A1

  公开（公告）日：2012-01-19

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.